This will complement the substantial experience that the company has gained with the SELUTION DeNovo trial in Europe.MedAlliances unique DEB technology involves MicroReservoirs which contain a mixture of biodegradable polymer intermixed with the anti-restenotic drug sirolimus applied as a coating on the surface of an angioplasty balloon.